Anton Ilich

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6065617/publications.pdf

Version: 2024-02-01

23	489	933447	713466
papers	citations	10	21
		h-index	g-index

23	23	23	745
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. British Journal of Cancer, 2019, 121, 359-371.	6.4	78
2	Global assays of fibrinolysis. International Journal of Laboratory Hematology, 2017, 39, 441-447.	1.3	70
3	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood, 2020, 135, 755-765.	1.4	61
4	Thrombin generation and cellâ€dependent hypercoagulability in sickle cell disease. Journal of Thrombosis and Haemostasis, 2016, 14, 1941-1952.	3.8	53
5	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood, 2019, 133, 2529-2541.	1.4	51
6	Red blood cell adhesion to hemeâ€activated endothelial cells reflects clinical phenotype in sickle cell disease. American Journal of Hematology, 2018, 93, 1050-1060.	4.1	36
7	Red blood cell adhesion to ICAM-1 is mediated by fibrinogen and is associated with right-to-left shunts in sickle cell disease. Blood Advances, 2020, 4, 3688-3698.	5.2	28
8	Development and application of global assays of hyperâ€•and hypofibrinolysis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 46-53.	2.3	23
9	Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. Blood Advances, 2022, 6, 3367-3377.	5.2	17
10	Plasmin-mediated Cleavage of High Molecular Weight Kininogen Contributes to Acetaminophen-Induced Acute Liver Failure. Blood, 2021, 138, 259-272.	1.4	14
11	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. Thrombosis Research, 2020, 191, S31-S36.	1.7	10
12	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. Oncologist, 2020, 25, 1075-1083.	3.7	9
13	Global assays of fibrinolysis. International Journal of Laboratory Hematology, 2017, 39, e142-e143.	1.3	8
14	Protease: Serpin complexes to assess contact system and intrinsic pathway activation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 789-798.	2.3	8
15	Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo. Blood Coagulation and Fibrinolysis, 2021, 32, 172-179.	1.0	6
16	Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma. Thrombosis Research, 2021, 204, 22-28.	1.7	6
17	<scp>Antithrombinâ€III</scp> mitigates thrombinâ€mediated endothelial cell contraction and sickle red blood cell adhesion in microscale flow. British Journal of Haematology, 2022, 198, 893-902.	2.5	3
18	Pathologically stiff erythrocytes impede contraction of blood clots: Comment. Journal of Thrombosis and Haemostasis, 2021, 19, 2893-2894.	3.8	2

#	Article	IF	Citations
19	Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease. Blood, 2016, 128, 2478-2478.	1.4	2
20	Histones Induce the Release of Extracellular Hemoglobin and Red Blood Cell-Derived Microvesicles with Procoagulant Activity. Blood, 2018, 132, 2514-2514.	1.4	2
21	Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer. Blood, 2019, 134, 634-634.	1.4	1
22	Cleavage of High Molecular Weight Kininogen and Bradykinin Release By Red Blood Cell Microvesicles As a Putative Mechanism for Hypotensive Transfusion Reactions. Blood, 2021, 138, 3240-3240.	1.4	1
23	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thrombosis Research, 2020, 196, 437-443.	1.7	0